AICAR

Source-reported examples · not treatment recommendations

Amount

1–3 mg per day; a separate higher-dose example reaches 5 mg

Frequency

Once daily

Cycle / observation period

8–12 weeks

Route / research model

Subcutaneous

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• Narkar and colleagues reported that four weeks of AICAR treatment increased running endurance by 44% in sedentary mice. The same paper investigated a PPAR-delta agonist with exercise, a distinct intervention that should not be merged into the AICAR result. The experiment supports a preclinical exercise-mimetic research concept. It is not a trial of athletic performance in humans. ^[1]
• An original cell study found that AICAR increased TXNIP expression through MondoA-dependent signaling without requiring AMPK activation. The investigators linked this response to uptake and metabolism into adenine nucleotides. ^[2]
• RED-CABG tested acadesine in people undergoing coronary artery bypass graft surgery. The trial planned a larger enrollment but stopped for futility after 3,080 participants had been randomized. Its primary composite endpoint included death, nonfatal stroke and severe left-ventricular dysfunction requiring mechanical support through 28 days. The reported event rates were 5.0% with placebo and 5.1% with acadesine, with no significant benefit. ^[3]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 14 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. 2008 Cell paper
2. MondoA study
3. 2012 randomized trial
4. U.S. Anti-Doping Agency (USADA)Further reading · Listed in reference bibliography.
5. PubMedFurther reading · Listed in reference bibliography.
6. PMC (PubMed Central)Further reading · Listed in reference bibliography.
7. MDPI (International Journal of Molecular Sciences)Further reading · Listed in reference bibliography.
8. PubMedFurther reading · Listed in reference bibliography.
9. JAMA NetworkFurther reading · Listed in reference bibliography.
10. MedlinePlus Medical EncyclopediaGeneral guidance · Listed in reference bibliography.
11. CDCGeneral guidance · Listed in reference bibliography.
12. Endocrinology (Oxford University Press)Further reading · Listed in reference bibliography.
13. PMCFurther reading · Listed in reference bibliography.
14. NCBI BookshelfFurther reading · Listed in reference bibliography.
15. PMCFurther reading · Listed in reference bibliography.
16. Biolog Life Science InstituteFurther reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.